Patient Safety

Half2023-Year Report

Key Figures

5-Year Overview H1 2019-2023 (in CHF million)

Net Sales

Net Profit

2019

2020

2021

2022

2023

2019

2020

2021

2022

2023

135.4

103.9

143.5

134.9

131.4

7.9

0.3

18.2

12.1

10.0

EBIT

2019

2020

2021

2022

2023

12.8

2.6

26.0

16.7

14.4

Free Cash Flow

2019

2020

2021

2022

2023

1.3

3.1

8.9

7.8

16.7

H1 Net Sales by Region in %

47.2 35.4 11.1

  2023   2022

6.3

North America

Latin America

EMEA

Asia

45.7

6.7

36.8

10.8

Highlights H1 2023

1.7%

Local-currency sales growth

In local currency terms, sales increased in a ­challenging business environment.

16.7 m

CHF, free cash flow

Free cash flow was strong thanks to improved net working capital.

92%

Product portfolio MDR certified

By H1 2023, nearly all sales came from EU Medical Device Regulation (MDR) certified products.

2.8 m

CHF, reduction of inventories

Inventories went down as backlogs were reduced and warehouse management was optimized.

3

The backlogs were successfully reduced.

Foreword

Dear Shareholders,

In the first half (H1) of 2023, the COLTENE Group achieved a pleasing business performance in a challenging environment. Net sales were CHF 131.4 million. At constant exchange rates, this corresponds to an impressive 1.7% increase year-on-year, up from a strong H1 2022 still riding the economic recovery after pandemic lockdowns were lifted. In reporting currency terms, however, net sales were down 2.6% from a year earlier (CHF 134.9 million). Operating profit (EBIT) for H1 2023 was CHF 14.4 million (H1 2022: CHF 16.7 million). The EBIT margin was

11.0% (H1 2022: 12.4%) and net profit was CHF 10.0 million (H1 2022: CHF 12.1 million). Actions taken to optimize net working capital were highly effective, delivering a strong positive boost to free cash flow, which rose to CHF 16.7 million (H1 2022: CHF 7.8 million).

The backlogs affecting instrument reprocessing equipment as a result of supply chain bottlenecks were successfully reduced. At the same time, however, the state of the global economy weighed

on demand. Despite these challenges, sales in this product group were up, year-on-year. By contrast, endodontic file sales were prevented by delays in the

certification­ process caused by the notified body TÜV Süd. The certifications have now been issued, allowing our endodontic files to reach markets with

effect from H2 2023. In the core regions, some sales suffered in H1 2023 as retailers reduced their existing inventories of Dental Preservation and Efficient Treatment ­products. The greatest impact on sales, however, came from negative exchange rate effects driven by the euro (EUR), US (USD), and Canadian (CAD) currencies. These effects reduced reported net sales by 4.3% and impacted all four regions.

At constant exchange rates, sales by product group saw year-on-year changes as follows: Dental Preservation - 5.5%, Efficient Treatment +0.3%, and Infection Control +10.6%.

Digital Transformation increases Patient Safety and delivers Benefits for Dental Practices and Service Technicians

The COLTENE Group is far advanced on product certifications under the new EU Medical Device Regulation (MDR) and already meets the high product and process quality standards. However, the registration ­requirements have increased significantly and as such push up costs.

4

The outlook for H2 is posi- tive despite a challenging­ economic environment.

New product and service launches are imminent. These will not only increase patient safety but also save time in dental practices while ­providing helpful information for service technicians.

After debuting in the first quarter at the world's premier dental trade show, IDS in Cologne, Germany, these products will be launched in key COLTENE markets in H2 2023. Via the my.coltene digital platform, COLTENE/SciCan device data is analyzed and instrument reprocessing is documented ­automatically. The new IC-Track system for ­instrument sets used in patient treatment allows

tracing and tagging these sets throughout their cleaning, sterilization, and disinfection process for each individual patient. The system is also

compatible­ with older-generation and third-party equipment and as such makes a significant contribution to patient safety.

Outlook

The COLTENE Group looks to H2 2023 with confidence. We expect that our distribution partners will have cleared their inventories in the course of H2. We are also enthusiastic about the products and services we will be ­launching in the coming months to continue driving digital transformation at COLTENE and unlock new customer segments. In addition, COLTENE is going to benefit from the newly issued certifications that have cleared our endodontic files for sale and from further economic recovery in China. Given its healthy balance sheet, moreover, COLTENE is well positioned for growth through acquisitions.

Based on the factors listed, the Group confirms its medium-term target of an EBIT margin of 15% with sales growth modestly above the market average.

On behalf of the Board of Directors and Group Management, we would like to thank our employees for their hard work, dedication, and commitment. We also wish to thank our valued customers, business partners, and shareholders for the confidence they place in the COLTENE Group.

Sincerely yours,

Nick Huber

Martin Schaufelberger

Chairman of the Board of Directors

CEO

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Coltene Holding AG published this content on 04 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2023 06:39:37 UTC.